ZA201202418B - Antibodies specific for claudin 6 (cldn6) - Google Patents

Antibodies specific for claudin 6 (cldn6)

Info

Publication number
ZA201202418B
ZA201202418B ZA2012/02418A ZA201202418A ZA201202418B ZA 201202418 B ZA201202418 B ZA 201202418B ZA 2012/02418 A ZA2012/02418 A ZA 2012/02418A ZA 201202418 A ZA201202418 A ZA 201202418A ZA 201202418 B ZA201202418 B ZA 201202418B
Authority
ZA
South Africa
Prior art keywords
cldn6
claudin
antibodies specific
antibodies
specific
Prior art date
Application number
ZA2012/02418A
Other languages
English (en)
Inventor
Ugur Sahin
Ozlem Tureci
Michael Koslowski
Korden Walter
Stefan Woll
Maria Kreuzberg
Bernd Hubner
Michael Erdeljan
Original Assignee
Ganymed Pharmaceuticals Ag
Johannes Gutenberg-Universitat Mainz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09014136A external-priority patent/EP2322555A1/en
Application filed by Ganymed Pharmaceuticals Ag, Johannes Gutenberg-Universitat Mainz filed Critical Ganymed Pharmaceuticals Ag
Publication of ZA201202418B publication Critical patent/ZA201202418B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
ZA2012/02418A 2009-11-11 2012-04-03 Antibodies specific for claudin 6 (cldn6) ZA201202418B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26020209P 2009-11-11 2009-11-11
EP09014136A EP2322555A1 (en) 2009-11-11 2009-11-11 Antibodies specific for claudin 6 (CLDN6)
US36161810P 2010-07-06 2010-07-06
EP10006956 2010-07-06
PCT/EP2010/006888 WO2011057788A1 (en) 2009-11-11 2010-11-11 Antibodies specific for claudin 6 (cldn6)

Publications (1)

Publication Number Publication Date
ZA201202418B true ZA201202418B (en) 2013-06-26

Family

ID=43480734

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/02418A ZA201202418B (en) 2009-11-11 2012-04-03 Antibodies specific for claudin 6 (cldn6)

Country Status (29)

Country Link
US (5) US9487584B2 (https=)
EP (4) EP3305813B1 (https=)
JP (3) JP5889196B2 (https=)
KR (4) KR102317098B1 (https=)
CN (4) CN111875703B (https=)
AU (3) AU2010318316B2 (https=)
BR (1) BR112012011143B1 (https=)
CA (2) CA2775373C (https=)
CY (2) CY1120300T1 (https=)
DK (2) DK3305813T3 (https=)
ES (3) ES2649389T3 (https=)
HR (2) HRP20171749T1 (https=)
HU (2) HUE049404T2 (https=)
IL (2) IL218628B (https=)
LT (2) LT2499161T (https=)
ME (1) ME02943B (https=)
MX (3) MX385874B (https=)
NO (1) NO2499161T3 (https=)
NZ (2) NZ716587A (https=)
PL (3) PL3689911T3 (https=)
PT (2) PT2499161T (https=)
RS (2) RS56502B1 (https=)
RU (1) RU2675997C2 (https=)
SG (2) SG10202110692WA (https=)
SI (2) SI2499161T1 (https=)
SM (1) SMT201700566T1 (https=)
UA (2) UA128302C2 (https=)
WO (1) WO2011057788A1 (https=)
ZA (1) ZA201202418B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ドèȘ­ć–èŁ…çœź
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US12492253B1 (en) * 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
LT2398902T (lt) 2009-02-20 2023-12-27 Astellas Pharma Inc. VÄ—ĆŸio diagnostikos ir gydymo bĆ«dai bei kompozicijos
NZ716587A (en) 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
US9321842B2 (en) * 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
ES2703936T3 (es) * 2011-05-13 2019-03-13 Ganymed Pharmaceuticals Gmbh Anticuerpos para el tratamiento de un cĂĄncer que expresa la claudina 6
CN103320381B (zh) * 2012-03-23 2015-04-15 äžŠæ”·ćž‚ć„żç«„ćŒ»é™ą äž€ç§ć€šèƒœćčČç»†èƒžèĄšéąæ ‡ćż—ç‰©ćŠć…¶ç”šé€”
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California PrzeciwciaƂa i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP3766903A3 (en) * 2012-11-13 2021-02-17 BioNTech SE Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
WO2014075788A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EP3747465A1 (en) * 2013-07-31 2020-12-09 BioNTech AG Diagnosis and therapy of cancer involving cancer stem cells
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
PE20160870A1 (es) * 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
TWI712421B (zh) 2013-11-11 2020-12-11 æ—„ć•†äž­ć€–èŁœè—„è‚Ąä»œæœ‰é™ć…Źćž 搫æ”čèźŠçš„æŠ—é«”ćŻèźŠć€äč‹æŠ—ćŽŸç”ćˆćˆ†ć­
SI3126381T2 (sl) * 2014-04-01 2022-05-31 Biontech Cell&Gene Therapies Gmbh Claudin-6-specifični imunoreceptorji in t-celični epitopi
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
TWI880146B (zh) 2014-11-11 2025-04-11 æ—„ć•†äž­ć€–èŁœè—„è‚Ąä»œæœ‰é™ć…Źćž ćŒ…ć«ç¶“æ”čèźŠäč‹æŠ—é«”ćŻèźŠć€äč‹æŠ—ćŽŸç”ćˆćˆ†ć­çš„èł‡æ–™ćș«
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
WO2018105560A1 (ja) * 2016-12-07 2018-06-14 ć›œç«‹ć€§ć­Šæł•äșș性é˜Ș性歊 ïŒŁïœŒïœïœ•ïœ„ïœ‰ïœŽ ïŒ•æŠ—äœ“ă€ćŠăłăăźæŠ—äœ“ă‚’ć«æœ‰ă™ă‚‹ćŒ»è–Ź
EP3623384A4 (en) * 2017-05-08 2021-01-27 Osaka University ANTI-CLDN-5 ANTIBODY AND ACTIVE SUBSTANCE WITH THIS ANTIBODY
WO2019048040A1 (en) * 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
TW201938194A (zh) 2017-12-05 2019-10-01 æ—„ć•†äž­ć€–èŁœè—„è‚Ąä»œæœ‰é™ć…Źćž ćŒ…ć«ç”ćˆcd3揊cd137的æ”čèźŠçš„æŠ—é«”ćŻèźŠć€äč‹æŠ—ćŽŸç”ćˆćˆ†ć­
US20210054076A1 (en) * 2018-01-05 2021-02-25 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US12493039B2 (en) 2018-10-09 2025-12-09 Fukushima Medical University Biomarker for predicting the prognosis for an endometrial cancer patient
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
AU2020241896A1 (en) 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
CR20220049A (es) 2019-07-10 2022-03-02 Chugai Pharmaceutical Co Ltd Moléculas de unión a claudina-6 y usos de las mismas
CN111087465B (zh) 2019-12-24 2020-12-08 ćčżć·žćŒ»ç§‘性歊 侀种针ćŻčćŻ†è›‹ç™œ6çš„æŠ—äœ“ć¶è”èŻç‰©ćŠćș”甚
CA3174094A1 (en) 2020-03-31 2021-10-07 Shinya Ishii Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
CA3212530A1 (en) * 2021-03-05 2022-09-09 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn6 antibody and use thereof
JP2024511319A (ja) 2021-03-09 2024-03-13 ă‚Œăƒłă‚łă‚ą ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒŁïœ„ïŒ“ćŠăłïœƒïœŒïœ„ïœŽïŒ–ă«ç”ćˆă™ă‚‹ăƒ˜ăƒ†ăƒ­äșŒé‡äœ“抗䜓
JPWO2023053282A1 (https=) 2021-09-29 2023-04-06
WO2024022512A1 (en) * 2022-07-29 2024-02-01 Nanjing Legend Biotech Co., Ltd. Claudin-6 binding moieties and uses thereof
TW202434302A (zh) 2022-10-31 2024-09-01 æ—„ć•†ćź‰æ–Żæł°äŸ†èŁœè—„è‚Ąä»œæœ‰é™ć…Źćž ćŒ…ć«éĄžéžć—é«”ïŒ—ïŒïŒ˜é›™é‡äżƒæ•ˆćŠ‘ćŒ–ćˆç‰©äč‹æŠ—é«”è—„ç‰©è€‡ćˆé«”
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
CN116064622B (zh) * 2023-02-13 2023-10-13 äŒ˜çżè”›æ€(歊汉)ç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž Claudin6-mCherryæŠ„ć‘ŠćŸș曠CHO-K1çšłèœŹç»†èƒžæ Șćˆ¶ć€‡ćŠćș”甚
WO2024235175A1 (zh) 2023-05-12 2024-11-21 æ™șæłœç«„ćș·(ćčżć·ž)ç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž 抗cldn6æŠ—äœ“ćŠć…¶ç”šé€”
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119371534B (zh) * 2024-08-21 2025-05-27 ç™Ÿć‰ç”Ÿç‰©ćŒ»èŻ(ćčżć·ž)è‚Ąä»œæœ‰é™ć…Źćž äž€ç§çŽ§ćŻ†èżžæŽ„è›‹ç™œæŠ—äœ“e02ćŠć…¶ćș”甚
CN118754987B (zh) * 2024-08-21 2025-02-11 ćčżć·žç™Ÿć‰ç”Ÿç‰©ćˆ¶èŻæœ‰é™ć…Źćž äž€ç§çŽ§ćŻ†èżžæŽ„è›‹ç™œæŠ—äœ“h04ćŠć…¶ćș”甚
CN119320451B (zh) * 2024-08-21 2025-05-16 ç™Ÿć‰ç”Ÿç‰©ćŒ»èŻ(ćčżć·ž)è‚Ąä»œæœ‰é™ć…Źćž äž€ç§çŽ§ćŻ†èżžæŽ„è›‹ç™œæŠ—äœ“d03ćŠć…¶ćș”甚

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 ĐĄĐŒŃ–Ń‚ĐșлаĐčĐœ Đ‘Ń–Ń‡Đ”ĐŒ БаĐčĐŸĐ»ĐŸĐŽĐ¶Ń–Đșалс ĐĄ.А. ĐšĐŸĐŒĐżĐŸĐ·ĐžŃ†Ń–Ń ĐČĐ°ĐșŃ†ĐžĐœĐž (ĐČĐ°Ń€Ń–Đ°ĐœŃ‚Đž), ŃĐżĐŸŃŃ–Đ± стабілізації qs21 ĐČŃ–ĐŽĐœĐŸŃĐœĐŸ ĐłŃ–ĐŽŃ€ĐŸĐ»Ń–Đ·Ńƒ (ĐČĐ°Ń€Ń–Đ°ĐœŃ‚Đž), ŃĐżĐŸŃŃ–Đ± ĐżŃ€ĐžĐłĐŸŃ‚ŃƒĐČĐ°ĐœĐœŃ ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†Ń–Ń— ĐČĐ°ĐșŃ†ĐžĐœĐž
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
JP2003524384A (ja) * 1998-11-03 2003-08-19 ケドヘレックă‚č ăƒ†ă‚ŻăƒŽăƒ­ă‚žăƒŒă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ă‚Żăƒ©ă‚Šăƒ‡ă‚ŁăƒłćȘ’ä»‹æ©Ÿèƒœă‚’èȘżçŻ€ă™ă‚‹ăŸă‚ăźćŒ–ćˆç‰©ăŠă‚ˆăłæ–čæł•
EP1140970A4 (en) 1998-12-17 2003-10-22 Human Genome Sciences Inc 47 HUMAN SECRETED PROTEINS
JP2002536995A (ja) 1999-02-22 2002-11-05 ă‚€ăƒłă‚”ă‚€ăƒˆăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚čăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ç”è…žăźç–Ÿæ‚Łă«é–ąé€Łă™ă‚‹éșäŒć­
DK1185648T3 (da) 1999-06-02 2007-07-30 Genentech Inc FremgangsmÄder og sammensÊtninger til inhibition af neoplastisk cellevÊkst
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
WO2001003734A1 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Blocking immune response to a foreign antigen using an antagonist which binds to cd20
WO2001053312A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001051513A2 (en) 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferĂȘncia por rna especĂ­ficos de sequĂȘncia de rna
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001273150A1 (en) 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2416538A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EA013564B1 (ru) 2000-08-03 2010-06-30 ĐąĐ”Ń€Đ°ĐżĐ”ŃƒŃ‚ĐžĐș Đ„ŃŒŃŽĐŒĐ°Đœ ĐŸĐŸĐ»ĐžĐșĐ»ĐŸĐœĐ°Đ»Đ· Đ˜ĐœĐș. Đ“ŃƒĐŒĐ°ĐœĐžĐ·ĐžŃ€ĐŸĐČĐ°ĐœĐœŃ‹Đč ĐžĐŒĐŒŃƒĐœĐŸĐłĐ»ĐŸĐ±ŃƒĐ»ĐžĐœ Đž ŃĐŸĐŽĐ”Ń€Đ¶Đ°Ń‰Đ°Ń Đ”ĐłĐŸ Ń„Đ°Ń€ĐŒĐ°Ń†Đ”ĐČтОчДсĐșая ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†ĐžŃ
CN1487996B (zh) 2000-11-30 2010-06-16 ç±łćŸ·ćˆ—æ–Żć…Źćž 甹äșŽç”Ÿäș§äșșç±»æŠ—äœ“çš„èœŹćŸșć› èœŹæŸ“è‰Čäœ“ć•źéœżćŠšç‰©
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002329540A1 (en) * 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2379661A1 (en) * 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN101928344B (zh) 2002-10-17 2014-08-13 æ čé©Źćžƒè‚Ąä»œć…Źćž 抗cd20的äșșć•ć…‹éš†æŠ—äœ“
JP2006516192A (ja) 2002-10-18 2006-06-29 ă‚žă‚§ăƒăƒłăƒ†ăƒƒă‚Żăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹăƒŒăƒ†ăƒƒăƒ‰ è…«ç˜ăźèšșæ–­ăšæČ»ç™‚ăźăŸă‚ăźç”„æˆç‰©ăšæ–čæł•
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2006033664A1 (en) 2004-03-08 2006-03-30 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
KR20130108481A (ko) * 2005-08-19 2013-10-02 ì•„ëłŽíŠž ëŸŹëłŽëŸŹí„°ëŠŹìŠˆ 읎원 ê°€ëł€ 도메읞 ë©Žì—­êž€ëĄœë¶ˆëŠ° 및 읎의 용도
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
KR101722261B1 (ko) * 2006-10-02 2017-04-03 메닀렉슀, 엘.엘.시. ïŒŁïœ˜ïœƒïœ’4에 êČ°í•©í•˜ëŠ” 읞간 항ìČŽ 및 읎의 용도
CA2668484A1 (en) * 2006-11-13 2008-05-22 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies 180706-02
WO2008114733A1 (ja) * 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗䜓
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) * 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗䜓
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CN101918450A (zh) * 2008-01-11 2010-12-15 ć›œç«‹ć€§ć­Šæł•äșș侜äșŹć€§ć­Š 抗cldn6抗䜓
CA2721072A1 (en) 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
DE102009026966A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Betrieb eines BremskraftverstÀrkers als Pedalsimulator
LT2398902T (lt) 2009-02-20 2023-12-27 Astellas Pharma Inc. VÄ—ĆŸio diagnostikos ir gydymo bĆ«dai bei kompozicijos
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
NZ716587A (en) * 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US9321842B2 (en) 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen fĂŒr gynĂ€kologisches Malignom und deren Verwendung
US20150166630A1 (en) 2012-07-19 2015-06-18 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof
WO2014075788A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
SI3126381T2 (sl) * 2014-04-01 2022-05-31 Biontech Cell&Gene Therapies Gmbh Claudin-6-specifični imunoreceptorji in t-celični epitopi

Also Published As

Publication number Publication date
BR112012011143B1 (pt) 2020-05-19
JP2017140041A (ja) 2017-08-17
HUE035516T2 (en) 2018-05-28
RU2675997C2 (ru) 2018-12-25
US10745477B2 (en) 2020-08-18
KR20190031335A (ko) 2019-03-25
AU2016202235B2 (en) 2017-12-07
EP3305813A1 (en) 2018-04-11
RS56502B1 (sr) 2018-02-28
US20200339677A1 (en) 2020-10-29
AU2018201640A1 (en) 2018-04-05
AU2010318316A1 (en) 2012-04-26
MX2020011790A (es) 2020-11-24
DK2499161T3 (da) 2017-11-27
CN105348389B (zh) 2019-12-20
RU2012123995A (ru) 2013-12-20
US20120308478A1 (en) 2012-12-06
SG10202110692WA (en) 2021-12-30
LT2499161T (lt) 2017-11-27
US20180162938A1 (en) 2018-06-14
CA3050655A1 (en) 2011-05-19
CN106432500A (zh) 2017-02-22
RS60168B1 (sr) 2020-05-29
EP2499161B1 (en) 2017-09-06
US20160222125A1 (en) 2016-08-04
CN106432500B (zh) 2020-06-02
HUE049404T2 (hu) 2020-09-28
HRP20200591T1 (hr) 2020-07-10
LT3305813T (lt) 2020-05-11
JP6125604B2 (ja) 2017-05-10
WO2011057788A1 (en) 2011-05-19
CA2775373C (en) 2019-10-29
PL3689911T3 (pl) 2024-11-18
ES2988907T3 (es) 2024-11-22
EP3305813B1 (en) 2020-01-15
HRP20171749T1 (hr) 2018-01-26
PL2499161T3 (pl) 2018-03-30
CN111875703B (zh) 2024-06-04
SI3305813T1 (sl) 2020-07-31
NZ716587A (en) 2017-10-27
JP2016047845A (ja) 2016-04-07
CN105348389A (zh) 2016-02-24
JP6502992B2 (ja) 2019-04-17
SMT201700566T1 (it) 2018-01-11
MX2012005444A (es) 2012-06-19
AU2018201640B2 (en) 2020-04-30
NZ734307A (en) 2020-05-29
EP3689911C0 (en) 2024-08-21
PL3305813T3 (pl) 2021-04-19
KR20120115226A (ko) 2012-10-17
SI2499161T1 (sl) 2017-12-29
CA3050655C (en) 2026-01-06
US9487584B2 (en) 2016-11-08
EP4461354A3 (en) 2025-03-19
JP2013510808A (ja) 2013-03-28
ES2649389T3 (es) 2018-01-11
IL218628A0 (en) 2012-05-31
SG10201500975YA (en) 2015-04-29
BR112012011143A2 (pt) 2016-11-29
MX385874B (es) 2025-03-18
JP5889196B2 (ja) 2016-03-22
CN102741289A (zh) 2012-10-17
EP2499161B8 (en) 2017-10-25
HK1253300A1 (en) 2019-06-14
PT2499161T (pt) 2017-12-05
US11858988B2 (en) 2024-01-02
AU2010318316B2 (en) 2016-01-14
KR102126964B1 (ko) 2020-06-25
ME02943B (me) 2018-10-20
MX347150B (es) 2017-04-17
IL246710B (en) 2020-05-31
NO2499161T3 (https=) 2018-02-03
ES2784483T3 (es) 2020-09-28
KR20210130250A (ko) 2021-10-29
EP4461354A2 (en) 2024-11-13
EP3689911A1 (en) 2020-08-05
US20240092896A1 (en) 2024-03-21
EP3689911B1 (en) 2024-08-21
UA128302C2 (uk) 2024-06-05
CY1123192T1 (el) 2021-10-29
UA117799C2 (uk) 2018-10-10
PT3305813T (pt) 2020-04-22
KR101960509B1 (ko) 2019-03-20
CY1120300T1 (el) 2019-07-10
KR20200075903A (ko) 2020-06-26
DK3305813T3 (da) 2020-04-20
CN111875703A (zh) 2020-11-03
IL246710A0 (en) 2016-08-31
KR102317098B1 (ko) 2021-10-25
US9932401B2 (en) 2018-04-03
CA2775373A1 (en) 2011-05-19
CN102741289B (zh) 2016-08-03
EP2499161A1 (en) 2012-09-19
IL218628B (en) 2018-12-31

Similar Documents

Publication Publication Date Title
IL246710A0 (en) Antibodies specific for claudin 6 (cldn6)
AU2016202235A1 (en) Antibodies specific for Claudin 6 (CLDN6)
GB0708002D0 (en) Antibodies
SI2200700T1 (sl) Nova protitelesa
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
SI3023438T1 (sl) Anti-GITR protitelesa
GB0909906D0 (en) Antibodies
GB0821100D0 (en) Antibodies
IL200437A0 (en) Anti-sclerostin antibodies
PL2195026T3 (pl) PrzeciwciaƂa przeciw sklerostynie
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
GB0718737D0 (en) Antibodies
IL207581A0 (en) Anti-tyrp1 antibodies
GB0702888D0 (en) Novel Antibodies
GB0920324D0 (en) Antibodies
ZA201007976B (en) Anti-pirb antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0818356D0 (en) Antibodies
GB0724185D0 (en) Antibodies
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies
GB0908945D0 (en) Antibodies